KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Xenon Pharmaceuticals (XENE) Restructuring Costs: 2022-2024

Historic Restructuring Costs for Xenon Pharmaceuticals (XENE) over the last 3 years, with Dec 2024 value amounting to $20.7 million.

  • Xenon Pharmaceuticals' Restructuring Costs rose 47.36% to $6.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $23.8 million, marking a year-over-year change of. This contributed to the annual value of $20.7 million for FY2024, which is 43.69% up from last year.
  • Latest data reveals that Xenon Pharmaceuticals reported Restructuring Costs of $20.7 million as of FY2024, which was up 43.69% from $14.4 million recorded in FY2023.
  • In the past 5 years, Xenon Pharmaceuticals' Restructuring Costs registered a high of $20.7 million during FY2024, and its lowest value of $10.0 million during FY2022.
  • Moreover, its 3-year median value for Restructuring Costs was $14.4 million (2023), whereas its average is $15.0 million.
  • Data for Xenon Pharmaceuticals' Restructuring Costs shows a peak YoY spiked of 43.82% (in 2023) over the last 5 years.
  • Xenon Pharmaceuticals' Restructuring Costs (Yearly) stood at $10.0 million in 2022, then spiked by 43.82% to $14.4 million in 2023, then spiked by 43.69% to $20.7 million in 2024.